Filing Flows › Niagen Bioscience (NAGE) › Q4 2025
Niagen Bioscience (NAGE) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 4, 2026
Niagen Bioscience (NAGE) reported revenue of $33.8M for the fourth quarter 2025 (Q4 2025), +16% from a year earlier and -0.4% from the quarter before. Operating margin was 12.1%, net earnings $4.1M (12.2% of revenue).
Niagen Bioscience, Q4 2025: revenue $33.8M (+16% year over year), operating margin 12.1%, net earnings $4.1M, operating cash flow $679K. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $33.8M | -0.4% | +16% |
| Gross profit | $21.7M | -1% | +19% |
| Operating profit | $4.1M | -4% | -43% |
| Net earnings | $4.1M | -10% | -42% |
| Operating cash flow | $679K | -82% | -92% |
What changed
Revenue was $33.8M in Q4 2025, up 16% year over year and roughly flat from the previous quarter.
Gross margin was 64.1%, up 1.7 points from a year earlier. Operating profit was $4.1M, a 12.1% margin (down 12.3 points year over year). Operating profit fell $3.0M even though revenue rose $4.7M versus a year earlier, so costs grew faster than sales. Operating expenses grew 59% against revenue growth of 16%. Net earnings were $4.1M, down 42% year over year. The effective tax rate was 6.6%.
Operating cash flow was $679K (down 92% year over year), 16% of net earnings. Non-cash charges added back $199K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items used $5.4M.
Questions
What was Niagen Bioscience's revenue in the fourth quarter 2025?
Niagen Bioscience (NAGE) reported revenue of $33.8M for the fourth quarter 2025 (Q4 2025), +16% from a year earlier and -0.4% from the quarter before.
Was Niagen Bioscience profitable in the fourth quarter 2025?
Operating profit was $4.1M (12.1% of revenue) and net earnings $4.1M.
Source: Niagen Bioscience 10-K on SEC EDGAR.